Targets › TNFSF11
4 programs from 4 companies in 30 trials: 15 Phase 4, 9 Phase 2, 5 Phase 3, 1 Phase 1; Metabolic and endocrine, Oncology, Genitourinary; next expected readout Dec 2026.
Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. (UniProt, O14788)
Open in Phaseline: the race on TNFSF11, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Amgen | Denosumab Tumor necrosis factor ligand superfamily member 11 inhibitor | TNFSF11 | Phase 4 | Osteoporosis; Glucocorticoid-induced Osteoporosis; Giant Cell Tumor of Bone; Osteoporosis, Postmenopausal … | Jan 2027 |
| Qilu Pharmaceutical | Denosumab (QL1206) Tumor necrosis factor ligand superfamily member 11 inhibitor | TNFSF11 | Phase 3 | Postmenopausal Women With Osteoporosis at High Risk of Fracture | Jan 2027 |
| Luye Pharma Group | LY06006 RANKL inhibitor | TNFSF11 | Phase 3 | Osteoporosis, Postmenopausal | – |
| Fudan University | Narlumosbart Anti-RANKL monoclonal antibody (IgG4) | TNFSF11 | Phase 2 | NSCLC | Dec 2026 |
Osteoporosis (7) Osteoporosis, Postmenopausal (2) Breast Cancer (2) Postmenopausal Women With Osteoporosis at High Risk of Fracture (1) NSCLC (1) Glucocorticoid-induced Osteoporosis (1) Giant Cell Tumor of Bone (1) Kidney Diseases (1) Sarcopenia in Elderly (1) Cystic Fibrosis (1) Postmenopausal Osteoporosis (1) Fibrous Dysplasia (1)
antibody (3), small molecule (1)
Qilu Pharmaceutical (1) Fudan University (1) Amgen (1) Luye Pharma Group (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.